[go: up one dir, main page]

EP1682565A4 - Oligomeres de nucleobases iap et complexes oligomeres, et leur utilisation - Google Patents

Oligomeres de nucleobases iap et complexes oligomeres, et leur utilisation

Info

Publication number
EP1682565A4
EP1682565A4 EP04789809A EP04789809A EP1682565A4 EP 1682565 A4 EP1682565 A4 EP 1682565A4 EP 04789809 A EP04789809 A EP 04789809A EP 04789809 A EP04789809 A EP 04789809A EP 1682565 A4 EP1682565 A4 EP 1682565A4
Authority
EP
European Patent Office
Prior art keywords
nucleobase oligomers
oligomer
oligomeric complexes
complexes
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04789809A
Other languages
German (de)
English (en)
Other versions
EP1682565A1 (fr
Inventor
Eric Lacasse
Daniel Mcmanus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aegera Therapeutics Inc
Original Assignee
Aegera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aegera Therapeutics Inc filed Critical Aegera Therapeutics Inc
Publication of EP1682565A1 publication Critical patent/EP1682565A1/fr
Publication of EP1682565A4 publication Critical patent/EP1682565A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention porte sur des oligomères de nucléobases IAP, sur des complexes oligomères, inhibant l'expression de polypeptides IAP et sur leurs méthodes d'utilisation pour induire l'apoptose de cellules. Lesdits oligomères et complexes oligomères peuvent entrer dans la composition de préparations pharmaceutiques . L'invention porte également sur des procédés d'accroissement de l'apoptose cellulaire par administration de tels oligomères ou complexes d'oligomères, associé à un agent chimiothérapeutique ou chimiosensibilateur.
EP04789809A 2003-10-30 2004-10-29 Oligomeres de nucleobases iap et complexes oligomeres, et leur utilisation Withdrawn EP1682565A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51619203P 2003-10-30 2003-10-30
PCT/CA2004/001902 WO2005042558A1 (fr) 2003-10-30 2004-10-29 Oligomeres de nucleobases iap et complexes oligomeres, et leur utilisation

Publications (2)

Publication Number Publication Date
EP1682565A1 EP1682565A1 (fr) 2006-07-26
EP1682565A4 true EP1682565A4 (fr) 2007-07-04

Family

ID=34549499

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04789809A Withdrawn EP1682565A4 (fr) 2003-10-30 2004-10-29 Oligomeres de nucleobases iap et complexes oligomeres, et leur utilisation

Country Status (5)

Country Link
US (1) US20050148535A1 (fr)
EP (1) EP1682565A4 (fr)
JP (1) JP2007510408A (fr)
CA (1) CA2542904A1 (fr)
WO (1) WO2005042558A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4032897B1 (fr) 2003-05-30 2025-01-29 Gilead Pharmasset LLC Analogues de nucléoside fluorés modifiés
US20050113328A1 (en) * 2003-11-06 2005-05-26 Devi Gayathri R. Method and antisense compound for potentiating anti-cancer agents
WO2005068616A2 (fr) 2004-01-16 2005-07-28 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Immunokinases
EP1800695A1 (fr) 2005-12-21 2007-06-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immuno-RNA conjugues
BRPI0711182A2 (pt) * 2006-05-03 2011-08-23 Baltic Technology Dev agentes anti-sentido combinando base fortemente ligada-oligonucleotìdeo modificado e nuclease artificial
EP1865071A1 (fr) * 2006-06-09 2007-12-12 Rheinische Friedrich-Wilhelms-Universität Bonn Méthode de diagnostic précoce de la rétinopathie diabétique proliférative
WO2012079075A1 (fr) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Dérivés de phtalimide deutérés
WO2013130849A1 (fr) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Dérivés de phthalimide dioxopipéridinyle substitués
WO2013159026A1 (fr) 2012-04-20 2013-10-24 Concert Pharmaceuticals, Inc. Rigosertib deutéré
WO2014066243A1 (fr) 2012-10-22 2014-05-01 Concert Pharmaceuticals, Inc. Formes solides de {s-3-(4-amino-1-oxo-isoindolin-2yl)(pipéridine-3,4,4,5,5-d5)-2,6-dione}
WO2014110322A2 (fr) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Dérivés substitués de dioxopipéridinyl phtalimide
KR102456433B1 (ko) 2016-03-02 2022-10-19 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린-기반 항체-약물 콘주게이트 및 사용 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087173A (en) * 1999-09-09 2000-07-11 Isis Pharmaceuticals Inc. Antisense modulation of X-linked inhibitor of apoptosis expression
US6673917B1 (en) * 2000-09-28 2004-01-06 University Of Ottawa Antisense IAP nucleic acids and uses thereof
US20040005593A1 (en) * 2002-03-06 2004-01-08 Rigel Pharmaceuticals, Inc. Novel method for delivery and intracellular synthesis of siRNA molecules
BR0308923A (pt) * 2002-03-27 2005-01-04 Aegera Therapeutics Inc OligÈmeros de nucleobase de iap anti-sentido e empregos destes
EP1469070A1 (fr) * 2003-04-15 2004-10-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts SiARNs specifique pour la Livin pour traiter les tumeurs resistantes aux therapies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHAWLA-SARKAR M ET AL: "TRAIL-RESISTANT CELLS SENSITIZED TO APOPTOSIS BY SELECTIVE DOWN REGULATION BY SIRNAS TO INHIBITORS OF APOPTOSIS BCL-2, FLIP, SURVIVIN OR XIAP", EUROPEAN CYTOKINE NETWORK, JOHN LIBBEY EUROTEXT LTD., MONTROUGE, FR, vol. 14, no. SUPPL 3, 20 September 2003 (2003-09-20), pages 112, XP009042059, ISSN: 1148-5493 *

Also Published As

Publication number Publication date
US20050148535A1 (en) 2005-07-07
WO2005042558A1 (fr) 2005-05-12
JP2007510408A (ja) 2007-04-26
CA2542904A1 (fr) 2005-05-12
EP1682565A1 (fr) 2006-07-26

Similar Documents

Publication Publication Date Title
WO2004084950A3 (fr) Procedes et compositions de ciblage cellulaire
WO2008155059A3 (fr) Mélanges d'hydrocarbures et leur utilisation
MX2010009850A (es) Analogos de insulina acilados y etabilizados contra proteasas.
ATE381893T1 (de) Aromapartikel
WO2004028475A3 (fr) Analogues du glycosylceramide
EP1682565A4 (fr) Oligomeres de nucleobases iap et complexes oligomeres, et leur utilisation
WO2008128775A3 (fr) Composition pharmaceutique stabilisée contenant de la prégabaline
MY146247A (en) Solid pharmaceutical dosage form comprising ritonavir
IL174154A (en) History of GLP-1 New Pharmaceutical Preparations Containing Them and Using It to Make Medicines
PL1909843T3 (pl) Przeciwnowotworowe biokoniugaty kwasu hialuronowego lub jego pochodne otrzymane przez pośrednie sprzęganie chemiczne i ich zastosowanie w dziedzinie farmacji
TW200508197A (en) Indolone-acetamide derivatives, processes for preparing them and their uses
TW200510344A (en) Aryl-heteroaromatic products, compositions comprising them and use
IL195935A0 (en) 18-methyl-19-nor-androst-4-en 17,17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
WO2008108808A3 (fr) Complexes dérivés de cellules hétérohybrides et utilisations de ceux-ci
WO2007057714A3 (fr) Compositions pharmaceutiques
WO2010052312A3 (fr) Médicament ou composition dermatologique comprenant un extrait peptidique d'avocat destiné au traitement et à la prévention du prurit
WO2002011724A3 (fr) Compositions de 2-pyridinamine et procedes associes
PL369754A1 (en) Immunocytokine-containing lyophilized preparation
WO2002012198A3 (fr) Derives 4-pyrimidinamines, compositions pharmaceutiques et procedes associes
WO2006072348A3 (fr) Thiophene substitue par un alkinyle
MXPA05008902A (es) Soluciones de drogas en mentol.
TW200630343A (en) 2-Alkoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
SE0300457D0 (sv) Novel compounds
WO2003059286A3 (fr) Procedes et compositions pour transport d'oxygene comprenant une hemoglobine modifiee dans le plasma
HK1093510A (en) Iap nucleobase oligomers and oligomeric complexes and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060530

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB

DAX Request for extension of the european patent (deleted)
RBV Designated contracting states (corrected)

Designated state(s): FR GB

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1093510

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: 8566

A4 Supplementary search report drawn up and despatched

Effective date: 20070601

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1093510

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100504